Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00050098.xml
CC BY-NC-ND 4.0 · Journal of Coloproctology 2023; 43(04): e286-e291
DOI: 10.1055/s-0043-1776889
DOI: 10.1055/s-0043-1776889
Original Article
Evaluation of Proactive Therapeutic Drug Monitoring Application in Infliximab Users in Ulcerative Colitis
Abstract
Objective To evaluate the application of proactive pro-drug therapy (TDM) at week six in users of infliximab therapy in ulcerative colitis patients and to analyze the need for further disease optimization.
Method This is a retrospective analysis that will be carried out simultaneously at the Hospital de Clínicas de Passo Fundo and at the Endoclin Diagnostic Center in the city of Passo Fundo, with secondary data collection between January 2020 and May 2022. The sample included patients from both sexes, regardless of age, who are being followed up in the services mentioned above, by signing the informed Free and Clarified Consent Term.
Results 63.2% of patients required optimization of their treatment based on the serum level assessment at week six.
Conclusion Proactive TDM performed at week six benefits patients in order to complete indications for treatment to avoid lack of drug response and complications from the disease.
Keywords
ulcerative colitis - colonoscopy - infliximab - remission induction - therapeutic drug monitoringPublication History
Received: 15 August 2023
Accepted: 24 October 2023
Article published online:
27 November 2023
© 2023. Sociedade Brasileira de Coloproctologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 Saad-Hossne R, Coy CSR. Atualização em doenças inflamatórias intestinais: conectando ciência à prática diária: curso de atualização do GEDIIB na SBAD 2019. São Paulo: Office; 2019
- 2 Pepercorn MA, Kane SV. Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults. Up To Date. 2022 . [accessed on May 29 2023]. Available from: https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-prognosis-of-ulcerative-colitis-in-adults?search=retocoliteulcerativa&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1
- 3 Ministério da Saúde. Protocolo Clínico e Diretrizes Terapêuticas da Retocolite Ulcerativa. Brasília: Ministério da Saúde; 2019. . [accessed on June 01 2023]. Available from: https://bvsms.saude.gov.br/bvs/publicacoes/protocolo_clinico_terapeuticas_retocolite_ulcerativa.pdf
- 4 Nemoz B, Ternant D, Bailly S. et al. New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases. Br J Clin Pharmacol 2019; 85 (04) 722-728 DOI: 10.1111/bcp.13845.
- 5 Dreesen E, Faelens R, Van Assche G. et al. Optimising infliximab induction dosing for patients with ulcerative colitis. Br J Clin Pharmacol 2019; 85 (04) 782-795 DOI: 10.1111/bcp.13859.
- 6 Scharnhorst V, Schmitz EMH, van de Kerkhof D, Derijks LJJ, Broeren MAC. A value proposition for trough level-based anti-TNFα drug dosing. Clin Chim Acta 2019; 489: 89-95 DOI: 10.1016/j.cca.2018.11.038.
- 7 Syversen SW, Jørgensen KK, Goll GL. et al. Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial. JAMA 2021; 326 (23) 2375-2384 DOI: 10.1001/jama.2021.21316.
- 8 Cassol OS, Zabot GP, Saad-Hossne R, Padoin A. Epidemiology of inflammatory bowel diseases in the state of Rio Grande do Sul, Brazil. World J Gastroenterol 2022; 28 (30) 4174-4181 DOI: 10.3748/wjg.v28.i30.4174.
- 9 Click B, Barnes EL, Cohen BL. et al. Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD. BMC Gastroenterol 2022; 22 (01) 71 DOI: 10.1186/s12876-022-02143-x.
- 10 da Silva BC, Lyra AC, Mendes CMC. et al. The Demographic and Clinical Characteristics of Ulcerative Colitis in a Northeast Brazilian Population. BioMed Res Int 2015; 2015: 359130 DOI: 10.1155/2015/359130.
- 11 Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci 1993; 38 (06) 1137-1146 DOI: 10.1007/BF01295733.
- 12 Portela F, Magro F, Lago P. et al. Ulcerative colitis in a Southern European country: a national perspective. Inflamm Bowel Dis 2010; 16 (05) 822-829 DOI: 10.1002/ibd.21119.
- 13 Lakatos L, Pandur T, David G. et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol 2003; 9 (10) 2300-2307 DOI: 10.3748/wjg.v9.i10.2300.
- 14 Brynskov J, Binder V. Arthritis and the gut. Eur J Gastroenterol Hepatol 1999; 11 (09) 997-999 DOI: 10.1097/00042737-199909000-00008.
- 15 Chan SSM, Luben R, Olsen A. et al. Body mass index and the risk for Crohn's disease and ulcerative colitis: data from a European Prospective Cohort Study (The IBD in EPIC Study). Am J Gastroenterol 2013; 108 (04) 575-582 DOI: 10.1038/ajg.2012.453.
- 16 Hashash JG, Vachon A, Ramos Rivers C. et al. Predictors of Suicidal Ideation Among IBD Outpatients. J Clin Gastroenterol 2019; 53 (01) e41-e45 DOI: 10.1097/MCG.0000000000001094.
- 17 Magro F, Gionchetti P, Eliakim R. et al; European Crohn's and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn's Colitis 2017; 11 (06) 649-670 DOI: 10.1093/ecco-jcc/jjx008.
- 18 Mosli MH, Zou G, Garg SK. et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2015; 110 (06) 802-819 , quiz 820 DOI: 10.1038/ajg.2015.120.
- 19 Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 2008; 14 (01) 53-57 DOI: 10.3748/wjg.14.53.
- 20 Shergill AK, Lightdale JR, Bruining DH. et al; American Society for Gastrointestinal Endoscopy Standards of Practice Committee. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 2015; 81 (05) 1101-21.e1 , 13 DOI: 10.1016/j.gie.2014.10.030.
- 21 Cohen RD, Stein AC. Management of moderate to severe ulcerative colitis in adults. Up To Date. 2021 . [accessed on May 15 2023]. Available from: https://www.uptodate.com/contents/management-of-moderate-to-severe-ulcerative-colitis-in-adults?search=retocoliteulcerativa&source=search_result&selectedTitle=4~150&usage_type=default&display_rank=4
- 22 A-Rahim YI, Farrell R. Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults. Up To Date. 2020 . [accessed on May 18 2023]. Available from: https://www.uptodate.com/contents/overview-of-dosing-and-monitoring-of-biologic-agents-and-small-molecules-for-treating-ulcerative-colitis-in-adults?search=retocoliteulcerativa&source=search_result&selectedTitle=7~150&usage_type=default&display_rank=7
- 23 Fucilini LMP, Genaro LM, Sousa DCE, Coy CSR, Leal RF, Ayrizono MLS. Epidemiological profile and clinical characteristics of inflammatory bowel diseases in a Brazilian referral center. Arq Gastroenterol 2021; 58 (04) 483-490 DOI: 10.1590/S0004-2803.202100000-87.
- 24 Chande N, Wang Y, MacDonald JK, McDonald JWD. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2014; 2014 (08) CD006618 DOI: 10.1002/14651858.CD006618.pub3.
- 25 Oren R, Arber N, Odes S. et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996; 110 (05) 1416-1421 DOI: 10.1053/gast.1996.v110.pm8613046.
- 26 Kelly OB, Donnell SO, Stempak JM, Steinhart AH, Silverberg MS. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease. Inflamm Bowel Dis 2017; 23 (07) 1202-1209 DOI: 10.1097/MIB.0000000000001126.
- 27 Queiroz NSF, Teixeira FV, Parra RS, Kotze PG. Induction therapeutic drug monitoring regimen with infliximab: A simplified evidence-based algorithm for inflammatory bowel disease. Arq Gastroenterol 2020; 57 (04) 507-510 DOI: 10.1590/S0004-2803.202000000-76.
- 28 Vande Casteele N, Ferrante M, Van Assche G. et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015; 148 (07) 1320-9.e3 DOI: 10.1053/j.gastro.2015.02.031.
- 29 Papamichael K, Van Stappen T, Vande Casteele N. et al. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2016; 14 (04) 543-549 DOI: 10.1016/j.cgh.2015.11.014.